October 17, 2019
  • October 17, 2019
Breaking News
  • Home
  • Prevail Therapeutics Inc.

Tag Archives

Laggard: Prevail Therapeutics Inc. (NASDAQ:PRVL)

by on July 2, 2019 0
New York-based Prevail Therapeutics (NASDAQ:PRVL) Prevail is a gene therapy company founded in 2017 that focuses on developing disease-modifying AAV-based gene therapies for neurodegenerative diseases by applying a precision medicine approach. The company’s lead compound PR001 is being evaluated for Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. The FDA has given its... Read More

Stock Touched New Highs: Epizyme, Inc. (NASDAQ:EPZM), Prevail Therapeutics Inc. (NASDAQ:PRVL), CEL-SCI Corporation (NYSE:CVM), Boot Barn Holdings, Inc. (NYSE:BOOT)

by on June 25, 2019 0
Epizyme, Inc. (NASDAQ:EPZM) has reported positive interim data from an ongoing Phase II trial of tazemetostat as a monotherapy to treat patients with relapsed or refractory follicular lymphoma (FL). The data shows that the company’s lead candidate tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in patients with EZH2 activating mutations, as well as with wild-type EZH2. Epizyme chief medical... Read More